Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III camrelizumab versus investigator's choice chemotherapy in relapsed or refractory classical Hodgkin lymphoma
CTR20200774Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in classical Hodgkin lymphoma (cHL), sponsored by Hengrui Therapeutics. Started Apr 2020; status: active.
02
Drugs
camrelizumab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on CTR20200774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200774.